NEW YORK, Oct. 5, 2016 /PRNewswire/ --
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional
oncology Company focused on the treatment of primary and metastatic
liver cancers, announces that Company management will
participate at the Dawson James Securities Growth Stock Conference
taking place on October 20, 2016 in
Jupiter, Florida. Jennifer K. Simpson, Ph.D., MSN, CRNP, President
and Chief Executive Officer of Delcath, will present a corporate
overview on October 20th at
2:15 p.m. Eastern
time.
Dr. Simpson's presentation at the Dawson James Securities
Growth Stock Conference will be webcast live and will be archived
on the Company's website at
www.delcath.com.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology
company focused on the treatment of primary and metastatic liver
cancers. Our investigational product—Melphalan Hydrochloride for
Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) —is designed to administer high-dose chemotherapy
to the liver while controlling systemic exposure and associated
side effects. We have commenced a global Phase 3 FOCUS clinical
trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a
global Phase 2 clinical trial in Europe and the U.S. to investigate the
Melphalan/HDS system for the treatment of primary liver cancer
(HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has
not been approved by the U.S. Food & Drug
Administration (FDA) for sale in the U.S. In Europe, our system has been commercially
available since 2012 under the trade name Delcath Hepatic CHEMOSAT®
Delivery System for Melphalan (CHEMOSAT), where it has been used at
major medical centers to treat a wide range of cancers of the
liver.
Safe Harbor / Forward-Looking Statements
Private Securities Litigation Reform Act of 1995 provides
a safe harbor for forward-looking statements made by the Company or
on its behalf. This news release contains forward-looking
statements, which are subject to certain risks and uncertainties
that can cause actual results to differ materially from those
described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the timing and results
of the Company's clinical trials including without limitation the
OM, HCC ,and ICC clinical trial programs, timely enrollment
and treatment of patients in the global Phase 3 FOCUS Clinical
Trial for Patients with Hepatic Dominant Ocular Melanoma and the
global Phase 2 HCC and ICC clinical trials, IRB or ethics committee
clearance of the Phase 2 HCC/ICC and/or Phase 3
OM protocols from participating sites and the timing of site
activation and subject enrollment in each trial, the impact, if
any, of publication of the Phase 3 trial manuscript to support the
Company's efforts,the impact of the presentations at major medical
conferences and future clinical results consistent with the data
presented, the impact, if any of ZE reimbursement on potential
CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting
sales, if any, for the CHEMOSAT system to deliver and filter
melphalan in Europe, the Company's
ability to successfully commercialize the CHEMOSAT/Melphalan HDS
system and the potential of the CHEMOSAT/Melphalan HDS system as a
treatment for patients with primary and metastatic disease in the
liver, our ability to obtain reimbursement for the CHEMOSAT system
in various markets, the Company's ability to satisfy the remaining
requirements of the FDA's Complete Response Letter and provide the
same in a timely manner, approval of the current or future
Melphalan HDS/CHEMOSAT system for delivery and filtration of
melphalan for various indications in the U.S. and/or in foreign
markets, actions by the FDA or other foreign regulatory agencies,
the Company's ability to successfully enter into strategic
partnership and distribution arrangements in foreign markets and
the timing and revenue, if any, of the same, uncertainties relating
to the timing and results of research and development projects, our
ability to maintain NASDAQ listing, and uncertainties regarding the
Company's ability to obtain financial and other resources for any
research, development, clinical trials and commercialization
activities. These factors, and others, are discussed from time to
time in our filings with the Securities and Exchange Commission.
You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after
the date they are made.
Contact Information:
Anne Marie Fields
LHA
212-838-3777
afields@lhai.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/delcath-to-present-at-the-dawson-james-securities-growth-stock-conference-300340074.html
SOURCE Delcath Systems, Inc.